Episode 899: Thrombolytic Contraindications - podcast episode cover

Episode 899: Thrombolytic Contraindications

Apr 15, 20244 min
--:--
--:--
Download Metacast podcast app
Listen to this episode in Metacast mobile app
Don't just listen to podcasts. Learn from them with transcripts, summaries, and chapters for every episode. Skim, search, and bookmark insights. Learn more

Episode description

Contributor: Travis Barlock MD

Educational Pearls:

  • Thrombolytic therapy (tPA or TNK) is often used in the ED for strokes

  • Use of anticoagulants with INR > 1.7 or PT >15

    • Warfarin will reliably increase the INR

  • Current use of Direct thrombin inhibitor or Factor Xa inhibitor

    • aPTT/PT/INR are insufficient to assess the degree of anticoagulant effect of Factor Xa inhibitors like apixaban (Eliquis) and rivaroxaban (Xarelto)

  • Intracranial or intraspinal surgery in the last 3 months

    • Intracranial neoplasms or arteriovenous malformations also increase the risk of bleeding

  • Current intracranial or subarachnoid hemorrhage

    • History of intracranial hemorrhage from thrombolytic therapy also contraindicates tPA/TNK

  • Recent (within 21 days) or active gastrointestinal bleed

  • Hypertension

    • BP >185 systolic or >110 diastolic

    • Administer labetalol before thrombolytics to lower blood pressure

  • Timing of symptoms

    • Onset > 4.5 hours contraindicates tPA

  • Platelet count

  • BGL

    • Potential alternative explanation for stroke-like symptoms obviating need for thrombolytics

References

1. Fugate JE, Rabinstein AA. Absolute and Relative Contraindications to IV rt-PA for Acute Ischemic Stroke. The Neurohospitalist. 2015;5(3):110-121. doi:10.1177/1941874415578532

2. Powers WJ, Rabinstein AA, Ackerson T, et al. Guidelines for the Early Management of Patients with Acute Ischemic Stroke: 2019 Update to the 2018 Guidelines for the Early Management of Acute Ischemic Stroke a Guideline for Healthcare Professionals from the American Heart Association/American Stroke Association. Vol 50.; 2019. doi:10.1161/STR.0000000000000211

Summarized by Jorge Chalit, OMSII | Edited by Jorge Chalit

For the best experience, listen in Metacast app for iOS or Android